Entrada Therapeutics Investor Relations Material

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular sites traditionally considered unreachable by conventional therapies. The company's proprietary Endosomal Escape Vehicle technology facilitates the efficient intracellular delivery of diverse therapeutic modalities, including RNA, antibodies, and enzymes. This approach is being applied to develop treatments for a range of diseases, particularly in neuromuscular, ocular, metabolic, and immunological areas. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.